Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

The employee awards carry a $10.65 exercise price and four-year vesting tied to continued service.

Rhea-AI Summary

Kura Oncology (KURA) granted stock options covering 128,250 common shares to new employees on October 1, 2026, as employment inducements.

The awards went to nine employees under the amended 2023 Inducement Option Plan and were approved under Nasdaq Listing Rule 5635(c)(4). The exercise price is $10.65 per share, matching the stock’s closing price on the grant date. Options vest over four years: 25% on the first anniversary of the applicable vesting commencement date, followed by monthly vesting of the balance over 36 months. Vesting requires continued service through each applicable vesting date.

Positive

• None.

Negative

• Minor point. Forward-looking: it has not happened yet and may not happen.Options covering 128,250 common shares at $10.65 per share create potential dilution if exercised.

News Explained

The award gives employees options to buy 128,250 shares, so any dilution depends on exercise; if exercised, added shares would reduce existing holders’ ownership percentages.

Key Figures

Options granted: 128,250 shares Recipients: 9 employees Exercise price: $10.65 per share +3 more

Options granted

128,250 shares

Inducement awards to new employees

Recipients

9 employees

New employees receiving inducement awards

Exercise price

$10.65 per share

Equal to the October 1, 2026 closing price

Vesting period

4 years

Subject to continued service

Initial vesting

25%

Vests on the one-year anniversary of the applicable vesting commencement date

Remaining vesting

36 months

Balance vests monthly after the initial one-year period

Historical Context

1 past event · Latest: Sep 04

1 event

1. Sep 04

   Inducement grant

   24h Move

   +0.8%

   Prior grant covered 48,450 shares for four employees, with a $12.89 exercise price and four-year vesting.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

nonstatutory stock options, nasdaq listing rule 5635(c)(4), menin inhibitor, nmp1-mutated acute myeloid leukemia

4 terms

nonstatutory stock options financial

"granted inducement awards consisting of nonstatutory stock options"

A nonstatutory stock option is a company-issued right that lets an employee or contractor buy shares later at a set price, but it does not qualify for special tax breaks. Think of it like a voucher to buy stock at today’s price; when used, the difference between market price and voucher price is taxed as ordinary income to the holder. Investors care because these options create potential share dilution, affect reported compensation costs, and influence employee incentives and cash flow when taxes and withholdings are settled.

nasdaq listing rule 5635(c)(4) regulatory

"in accordance with Nasdaq Listing Rule 5635(c)(4)"

NASDAQ Listing Rule 5635(c)(4) is a rule that requires a company to get approval from its shareholders before selling a large amount of its shares, usually over 20%. This helps protect investors by making sure the company doesn't flood the market with new shares without their say, which could lower the stock's value.

menin inhibitor medical

"the FDA-approved once-daily, oral menin inhibitor"

A menin inhibitor is a type of experimental drug that blocks the action of a protein called menin, which some cancers use to keep growing. Think of it as flipping off a switch that cancer cells rely on to survive; by doing so, these drugs can slow or stop tumor growth. Investors watch menin inhibitors because clinical trial results, regulatory approvals, and market demand determine whether they become valuable cancer treatments and potential revenue drivers.

nmp1-mutated acute myeloid leukemia medical

"adults with relapsed or refractory NPM1-mutated acute myeloid leukemia"

A subtype of acute myeloid leukemia (AML) defined by mutations in the NPM1 gene, which encodes the nucleophosmin protein. The NPM1 mutation causes abnormal localization of nucleophosmin to the cell cytoplasm and is a recognized diagnostic category in hematology that influences classification, prognostic assessment, and selection of therapies; it is identified by genetic testing of leukemia cells and can occur with varying co‑mutations that modify clinical behavior.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SAN DIEGO, Oct. 02, 2026 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (the “Company”) (Nasdaq: KURA), a biopharmaceutical company focused on precision medicines for the treatment of cancer, today announced that on October 1, 2026, the Compensation Committee of the Company’s Board of Directors (the “Compensation Committee”) granted inducement awards consisting of nonstatutory stock options to purchase 128,250 shares of common stock to nine (9) new employees under the Company’s 2023 Inducement Option Plan, as amended. The Compensation Committee approved the stock options as an inducement material to such employees’ employment in accordance with Nasdaq Listing Rule 5635(c)(4).

Each stock option has an exercise price equal to $10.65 per share, the closing price of the Company’s common stock on October 1, 2026, and will vest over four years, with 25% of the underlying shares vesting on the one-year anniversary of the applicable vesting commencement date and the balance of the underlying shares vesting monthly thereafter over 36 months, subject to the new employees’ continued service relationship with the Company through the applicable vesting dates. The stock options are subject to the terms and conditions of the Company’s 2023 Inducement Option Plan, as amended, and the terms and conditions of an applicable stock option agreement covering the grant.

About Kura Oncology
Kura Oncology is a biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer. Kura’s pipeline of small molecule drug candidates is designed to target cancer signaling pathways and address high-need hematologic malignancies and solid tumors. Kura developed and is commercializing KOMZIFTI^® (ziftomenib), the FDA-approved once-daily, oral menin inhibitor for the treatment of adults with relapsed or refractory NPM1-mutated acute myeloid leukemia, and continues to pioneer advancements in menin inhibition and farnesyl transferase inhibition. For additional information, please visit the Kura website and follow us on X and LinkedIn.

Kura Contact

Investors and Media:
Greg Mann
858-987-4046
gmann@kuraoncology.com

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many employee stock options did Kura Oncology grant and at what exercise price?

Kura Oncology granted options to purchase 128,250 common shares to nine new employees on October 1, 2026. Each option has an exercise price of $10.65 per share, equal to the stock’s closing price that day.

What is the vesting schedule for Kura Oncology’s October 2026 inducement options?

The options vest over four years, subject to continued service through the applicable vesting dates. The first 25% vests on the one-year anniversary of the applicable vesting commencement date, and the balance vests monthly over the following 36 months.